VNDA — Vanda Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $244.87m
- $82.02m
- $216.11m
US STOCKS ON THE MOVE-Walmart, Super Micro, FMC
US STOCKS ON THE MOVE-Nvidia, Penske Automotive, ManpowerGroup
US STOCKS ON THE MOVE-Barrick Mining, Venture Global, GE Vernova
Vanda Pharma shares slip as trial failure halts anxiety drug program
Vanda says anxiety drug failed main goal of late-stage study, puts program on hold
Brief: Vanda Pharmaceuticals Provides Update On Vqw-765 Clinical Development Program
Live Markets: Retail traders sit out volatile September as activity falls to lowest since late 2024
Brief: Vanda Pharmaceuticals Announces Positive Phase III Results For Hetlioz®(Tasimelteon) In Delayed Sleep-Wake Phase Disorder
Vanda Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Vanda Pharmaceuticals Q2 loss widens on lower sales, higher costs
Brief: Vanda Pharmaceuticals Q2 EPS USD -1.04
Vanda Pharmaceuticals Inc expected to post a loss of 59 cents a share - Earnings Preview
Brief: Vanda Pharmaceuticals Announces EMA Positive Opinion For Orphan Drug Designation Of Imsidolimab For GPP
Vanda Pharma Q1 revenue misses estimates, lifts 2026 outlook
Brief: Vanda Pharmaceuticals Announces U.S. Commercial Availability Of Nereus™ (Tradipitant), The First New Pharmacologic Treatment For People With Motion Sickness In More Than 40 Years
Brief: Vanda Pharmaceuticals US Availability Of Nereus For People With Motion Sickness
U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-Forman
U.S. STOCKS ON THE MOVE-Zscaler, Carlyle, Weight Watchers
Vanda urges FDA to drop proposal for extending drug review timelines; shares down